Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc.

Track NRXP — free

Use NRXP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NRXP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.27 -0.07 (-2.10%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$141.58M
Shares
43.30M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.27 Open$3.37 Day$3.16–3.40 52W close$1.68–4.62 Avg vol 30d1.1M Short int6.6M · 15.1% float · 7.6d Short vol54% Last earningsMay 18, 2026 DataApr 2024–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Apr 2, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg −14%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 54%
mid-range
Momentum
relative strength
Strong
1-month return −23%
trailing
6-month return +86%
trailing
YTD return +21%
this year
Relative strength +72%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+37% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.13% of float · ▲ +5.7% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
EPS growth +70%
Y/Y
Balance sheet $4.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −54%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
−14% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
54% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+37% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.13% of float · ▲ +5.7% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 54% Range high $5
vs 200-day avg +17% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NRXP
NRX Pharmaceuticals, Inc.
this stock
$141.58M +20.7% — — 15.1%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
48
% held
28.2%
Net QoQ
+5.7M sh
Top holder
B Group, Inc.
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Rising
Shares short
6.6M
Days to cover
7.6d
Change
+354.2K sh
View
Short Volume
Short vol %
54%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
27.4K
Value
$113.6K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
45.7%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.2M
Net income (FY)
$-28.6M
EPS diluted
$-6.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
15
View
Exempt Offerings
Offering
$3.5M
Filed
Mar 7, 2025
View
Earnings & Events
Earnings Calls
Last call
May 18, 2026
View
Investor Relations
Latest news
NRx Pharmaceuticals, Inc. (NASDAQ…
Published
Aug 7, 2026
View

Performance

Raw-price comparisons begin at the captured split on Apr 2, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NRXP -8.7% -23.4% +85.8% +3.8% +20.7%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -9.1% -27.9% +72.0% -0.1% +6.8%
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 47 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)